[Latest] Global Bispecific Antibodies Market Size/Share Worth USD 53.8 Billion by 2033 at a 24.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmen...
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Latest
Antibodies Market size & share revenue was valued at approximately USD 6.2 Billion in 2023 and is expected to reach USD 7.7 Billion in 2024 and is expected to reach around USD 53.8 Billion by 2033, at a CAGR of 24.1% between 2024 and 2033. The key market players listed in the report with their sales, revenues and strategies are Roche Holding AG, Amgen Inc., Novartis AG, Merck & Co. Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Eli Lilly and Company, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ablynx NV (A Sanofi Company), MorphoSys AG, Xencor Inc., Gilead Sciences Inc., AstraZeneca plc, Pfizer Inc., and others. Austin, TX, USA, April 04, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “ Bispecific Antibodies Market Size, Trends and Insights By Application (Cancer Therapy, Autoimmune Diseases), By Mechanism of Action (T-cell Engagement, Dual Target Binding), By Type (IgG-Like Molecules, F(ab)2-Like Molecules), By Target
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending [Seeking Alpha]Seeking Alpha
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at UBS Group AG from $284.00 to $307.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen Inc. (NASDAQ: AMGN) had its price target raised by analysts at Morgan Stanley from $271.00 to $310.00. They now have an "equal weight" rating on the stock.MarketBeat
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at Royal Bank of Canada from $332.00 to $328.00. They now have an "outperform" rating on the stock.MarketBeat
- Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 5/2/24 - Beat
AMGN
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- 5/3/24 - Form 4
- AMGN's page on the SEC website